Iressa Tablet, Coated
Product Images NDC 0310-0482

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Iressa (NDC 0310-0482). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Iressa 250mg Bottle Label

Label for IRESSA (gefitinib) tablets, 250 mg strength, oral coated tablets. Manufactured for AstraZeneca Pharmaceuticals LP, Wilmington, DE, and by AstraZeneca UK Limited, Macclesfield, Cheshire, England. The label shows a package containing 30 tablets with NDC 0310-0482-30. The AstraZeneca logo is present at the bottom right.*

FDA Label Image

Structural Formula For Gefitinib (Image 01)

Chemical structure of Gefitinib, the active ingredient in IRESSA 250 mg coated tablets by AstraZeneca Pharmaceuticals LP. The structure displays the molecular configuration with rings, atoms, and functional groups including a fluorine and chlorine substituent.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.